At Oria, we introduce a revolutionary technology that empowers drug discovery platforms to conduct high-frequency screening (HTS) on organelles (lysosomes, mitochondria, endoplasmic reticulum…). Our innovation involves the development of a fluidic process capable of purifying (extracting and sorting) up to 1 million organelles per hour. These whole organelles, retaining their native proteins, seamlessly integrate with pharmaceutical high throughput screening instruments and automated patch clamp, paving the way for new Hit-To-Lead and Lead optimization tests. Oria provides to pharmaceutical laboratories and CROs a new powerful tool for their platforms engaged in drug discovery, offering efficiency and compatibility crucial for successful screening processes.